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Abstract
Certain free fatty acids have been shown to have potent effects on food intake and self-reported
changes in appetite; effects associated with increases in the release of endogenous cholecystokinin
(CCK) and glucagon like peptide-1 (GLP-1). In the current study, the effects of a Korean pine nut
oil product, PinnoThin™, at doses 2 g, 4 g and 6 g triglyceride (TG) and 2 g free fatty acid (FFA),
on food intake and appetite were examined in a cross-over double-blind placebo-controlled
randomised counter-balanced design in 42 overweight female volunteers. 2 g FFA PinnoThin™,
given 30 minutes prior to an ad-libitum buffet test lunch, significantly reduced food intake (gram)
by 9% (F(4,164) = 2.637, p = 0.036) compared to olive oil control. No significant effect of
PinnoThin™ on macronutrient intake or ratings of appetite were observed. Given the recent data
showing that the TG form of PinnoThin™ may also reduce appetite by increasing CCK release, the
lack of any effect of the TG form found in this study could be attributed to the timing of the dosing
regime. Collectively, these data suggest that PinnoThin™ may exert satiating effects consistent with
its known action on CCK and GLP-1 release, and previously observed effects on self-reported
appetite ratings.
Background
Estimations of energy balance suggest that an increase in
daily caloric intake of 50 kcal more than energy expendi-
ture can result in a yearly increase in body weight of 1 or
2 kilos [1] contributing to the development of obesity. To
correct this positive energy balance one strategy in the
arena of weight management and prevention of obesity is
the control of food intake via natural appetite suppres-
sants.
The roles of different macronutrients in appetite suppres-
sion have been extensively studied. While it has generally
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strong satiety responses [2,3], high fat foods in particular
have been regarded as having a comparatively weaker
impact on appetite regulatory mechanisms [4]. In fact a
weakened satiety response to fatty meals has been associ-
ated with a susceptibility to weight gain [5].
Despite this, dietary fat in the gastro-intestinal tract has
been demonstrated to trigger the release of the satiety gut
hormones cholecystokinin (CCK) in the proximal small
intestine (duodenum), and glucagon like peptide-1 (GLP-
1) in the distal small intestine (ileum). The effects of fat
on appetite expression have long been associated with the
CCK response [6-11]. Moreover, in human volunteers,
exogenous CCK infusions reduce food intake and
enhance satiety [12-15]. GLP-1 is released in response to
nutrients [16,17] such as carbohydrate [18-20] and fat
[21,22]. In humans, peripheral GLP-1 infusions have
been shown to significantly enhance the satiating poten-
tial of a fixed caloric load [23] and also produce a reduc-
tion in intake at ad-libitum meals, effects which are
associated with reductions in hunger and enhancements
in satiety [23-28].
The release of endogenous CCK and GLP-1 suggests, par-
adoxically, that fat could exert strong effects on the devel-
opment of satiation and the strength of post-meal satiety,
despite an association between high fat over-consump-
tion and obesity [29]. Chain length and degree of satura-
tion may be important properties when considering the
effect of fat on the expression of human appetite. Feinle
and colleagues [30] demonstrated that duodenal infu-
sions of long chain triglycerides produced greater effects
on hunger and plasma CCK levels than medium chain
triglycerides, an effect dependent on hydrolysis of the trig-
lyceride (TG) to free fatty acid (FFA) form. Feltrin et al.,
(2004) [31] also demonstrated that duodenal infusions of
FFA of a chain length of C12 produced more potent effects
on food intake, appetite expression, CCK and GLP-1
release compared with a FFA of chain length of C10. With
regard to saturation, Lawton et al., (2000) [32] demon-
strated that polyunsaturated fatty acids (PUFA) of a chain
length C18, exert a stronger effect on appetite expression
than monounsaturated (MUFA) and saturated (SFA)
equivalent C18 forms. Degree of saturation (MUFA versus
SFA) also appears to affect endogenous GLP-1 response to
high fat meals [33,34]. Therefore, the divergent effects of
fats, both in chain length and saturation, on CCK and
GLP-1 release, and the expression of appetite, have impli-
cations for energy balance [4].
PinnoThin™ is a natural oil pressed from Korean pine nuts
(Pinus Koraiensis) and consists of 92% of PUFAs and
MUFAs, mainly pinolenic acid (C18:3), linoleic acid
(C18:2) and oleic acid (C18:1) [35]. Nut consumption is
popular worldwide and has been linked with satiety
[36,37]. Pine nuts have long been constituent parts of the
diets of many cultures, particularly in the Mediterranean
and Asian regions, and they are now also consumed very
widely outside these geographical areas. In vitro studies
on Korean pine nut fatty acids have shown an increase in
the release of CCK-8 from STC-1 cells vs. Fatty acids from
Italian stone pine nuts and also several other dietary
mono and poly unsaturated fatty acids [38]. It has recently
been shown that PinnoThin™ stimulates endogenous
CCK and GLP-1 release in overweight women when
simultaneously consumed with a fixed load breakfast
[38,39] and thereby has the potential to reduce prospec-
tive food intake.
There is however no information on whether PinnoThin™
can actually reduce food consumption. Therefore, the cur-
rent study was designed to assess the impact of Pin-
noThin™ on human food intake and appetite expression.
The present study had three aims: 1) to determine
whether PinnoThin™, given prior to consumption of a test
meal, would produce a significant reduction in kilocalorie
(kcal) intake in a subsequent ad-libitum meal, 2) to deter-
mine if any hypophagia produced by effective doses of
PinnoThin™ were accompanied by appropriate changes in
pre- and post-meal appetite ratings indicating any satiety
enhancing properties, and 3) to demonstrate that any sup-
plement-induced reductions in food intake were associ-
ated with a durable rather than a transient satiety
response, consistent with the reported physiological
mechanism of action. By examining ad-libitum intake at
an evening meal it will be possible to determine if any ini-
tial reductions in food intake produced by PinnoThin™
are compensated for by over consumption at later eating
opportunities.
Results
Participants
The study commenced in June 2006 and was completed
in February 2007. In total, 45 women were enrolled onto
the study. Of the 45 enrolled, 42 participants completed
all five conditions. One participant completed one morn-
ing and lunch session of one visit and withdrew due to
unrelated illness; one participant completed one full visit
but withdrew from the study due to illness, the cause of
which was unascertained; and one participant completed
two visits before withdrawing due to childminding prob-
lems. Figure 1 shows details of the number of enquiries,
participants screened and outcome. The demographic
(age), and anthropometric (weight, height, BMI) charac-
teristics of the completing participants, together with the
screening measure scores are shown in Table 1.Page 2 of 10
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Intake at lunch and supper together with combined intake
at lunch and supper (in grams and kcal) are shown in
Table 2. There was a significant main effect of condition
on food intake at the test meal (F(4,164) = 2.637, p =
0.036). A decrease in both the amount and energy content
of the food consumed at the buffet meal was seen in the
PinnoThin™FFA condition. This dose reduced gram intake
by 9% with post-hoc tests showing a significant difference
between the 2 g PinnoThin™FFA and placebo conditions
(t (41) = 2.270, p = 0.029). With regard to effect of condi-
tion on energy intake an insignificant trend was seen
(F(4,164) = 1.552, p = 0.190). Energy intake was reduced
by 7% from control in the PinnoThin FFA condition with
Total enquiries, participants screened and recruited to studyFigur  1
Total enquiries, participants screened and recruited to study.
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1.702, p = 0.096). The results stayed the same after exclu-
sion of outliers. No effects were seen for the other condi-
tions and no differences were seen in intake during
supper. No main effect of condition was found for macro-
nutrient content or the type of food.
VAS ratings of appetite
There were no significant effects of condition on subjec-
tive ratings of hunger, fullness, satisfaction, desire to eat,
prospective consumption, thirst or nausea. Additional
ANOVAs to investigate trends were run from the pre-dose
VAS ratings (T6) through to the post supper rating (T13).
No statistically significant scores were found.
Adverse events
No signs or symptoms of serious adverse events due to the
study product were reported. One participant reported
blotchiness on the palms of her hands which occurred
four days after the last visit. Un-blinding of the product
revealed the final visit was placebo and therefore the event
was completely unrelated to the product.
Discussion
The use of natural appetite suppressants may be a key
strategy to help prevent weight gain. Nuts have been stud-
ied for their satiation ability and contain fiber, protein
and oil and are highly nutritious. Many cultures use
Korean pine nuts in popular dishes. Korean Pine nut oil
(PinnoThin ™) which is high in pinolenic acid has previ-
ously been shown to increase CCK in STC-1 cell culture
and to have effects on satiety in response to a fixed caloric
load, such as increasing concentrations of CCK and GLP-
1 in humans [38]. Specific changes in satiety measures was
observed in prospective food consumption [38,39]. The
purpose of the study was to evaluate the effects of Pin-
noThin™ on subsequent food intake in an ad-libitum
meal. PinnoThin™FFA produced a significant 9% reduc-
tion in ad-libitum food intake thirty minutes after dosing
compared with the placebo control. No differences
between PinnoThin™ and the placebo were seen at the
evening meal, suggesting that there is no compensation
for the lesser food intake during lunch. No effect was pro-
duced by any of the three doses (2 g, 4 g or 6 g) of the Pin-
noThin™ TG.
No adverse effects related to the study product were
reported by participants during the full study period or at
post-study debriefing. No significant effect of product on
nausea was observed on study days. This indicates that
PinnoThin TG at various doses and PinnoThin FFA 2 g
Table 2: Macronutrient, energy and gram intakes at the test meals (mean ± SE)
Test Meal Intake Placebo PThin TG 2 g PThin TG 4 g PThin TG 6 g PThin FFA 2 g
LUNCH
Protein (g) 24.4 ± 1.5 24.5 ± 1.5 23.7 ± 1.5 24.6 ± 1.4 22.3 ± 1.4
Fat (g) 32.0 ± 2.1 32.1 ± 2.3 30.1 ± 1.9 32.4 ± 1.9 29.1 ± 2.0
Carbohydrate (g) 79.8 ± 5.4 82.3 ± 5.4 85.6 ± 5.6 81.7 ± 5.7 75.9 ± 5.0
Gram Intake (g) 380.2 ± 18.5 373.7 ± 21.3 386 ± 18.8 383.7 ± 18.2 349.7 ± 18.8*
Energy Intake (kcal) 706.1 ± 38.9 717.7 ± 41.6 709.5 ± 37.5 718.8 ± 38 656.2 ± 36.8
SUPPER
Protein (g) 37.9 ± 2.0 35.6 ± 2.0 36.7 ± 1.9 36.1 ± 1.7 37.4 ± 1.9
Fat (g) 21.0 ± 1.1 20.6 ± 1.1 20.6 ± 0.9 20.9 ± 1.2 21.6 ± 1.0
Carbohydrate (g) 165.6 ± 9.4 159.6 ± 8.8 166.2 ± 8.8 161.9 ± 8.0 170.3 ± 8.4
Gram Intake (g) 521.4 ± 27.4 508.4 ± 29.7 523.4 ± 25.9 513.7 ± 25.2 530.2 ± 24.1
Energy Intake (kcal) 1002.4 ± 50.8 965.4 ± 49.8 996.1 ± 46.3 979.1 ± 44.5 1024.4 ± 46.2
LUNCH & SUPPER
Protein (g) 62.4 ± 2.7 60.1 ± 2.9 60.4 ± 2.6 60.7 ± 2.4 59.7 ± 2.7
Fat (g) 53.0 ± 2.4 52.7 ± 2.7 50.6 ± 2.2 53.3 ± 2.2 50.8 ± 2.5
Carbohydrate (g) 245.4 ± 9.5 241.9 ± 10.8 251.8 ± 9.5 243.6 ± 9.6 246.2 ± 9.6
Gram Intake (g) 901.6 ± 39.3 882.1 ± 45.9 909.4 ± 38.3 897.4 ± 37.1 879.8 ± 38.5
Energy Intake (kcal) 1708.5 ± 59.6 1683.1 ± 69.1 1705.6 ± 55.6 1698 ± 58.9 1680.7 ± 62.5
* significantly different from placebo p < 0.05
Table 1: Baseline characteristics of subjects who completed the 
study (mean ± SD)
Mean (N = 42)
Age (years) 33.8 ± 15.6
Weight (kg) 73.9. ± 7.0
Height (m) 1.7 ± 0.7
BMI (kg/m2) 27.4 ± 1.3
DEBQ-R 3.0 ± 0.7
CES-D 11.3 ± 7.9Page 4 of 10
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completed the study.
The reduced food intake of 9% corresponded to a 7% (50
kcal) reduction in energy intake. Although this reduction
was not statistically significant, probably due to lack of
power (power calculations were based on a 10% differ-
ence), a reduction of 50 kcal is potentially biologically rel-
evant. Brown et al [1] estimated that the average weight
gain in a female population equates with an energy imbal-
ance of only 10–40 kcal per day. Post-hoc paired t-test
revealed that the difference in kcal intake between the
control and FFA condition would have been significant in
a one-way test. The slight disparity between the magni-
tude of gram and kcal intake reduction between the con-
trol and the FFA condition could suggest small treatment
induced effects of food choice i.e. a greater reduction in
the intake of less energy dense foods. However, no differ-
ence was seen between the intake of macronutrients,
sweet/savoury or high/low fat foods.
Both the PinnoThin™ FFA and TG forms have been shown
to have an effect on satiety by increasing levels of CCK
[38]. While the PinnoThin FFA reduced food intake, the
lack of effect of any dose of the PinnoThin™TG on food
intake in this trial remains unclear. Feinle et al., (2001)
[30] demonstrated that duodenal infusions of a long
chain TG can produce potent effects on plasma CCK levels
and significantly reduce hunger. This is consistent with
the known mechanisms of CCK release [11,40]. In the
Feinle study, effects of TG on CCK response and appetite
were blocked by the lipase inhibitor tetrahydrolipstatin.
Therefore, the uptake and metabolism of the precursor
triglycerides to the FFA form, the latter of which is respon-
sible for CCK and GLP-1 release, is needed to induce sati-
ety.
In the current study, the digestion of pine nut oil TG to
FFA form was not assessed. However, there is no reason to
believe that the actions of lipases were inhibited in any
way. The lack of effect may be explained by insufficient
time passed between the intake of the TG capsules and the
ad-libitum lunch for lipase action to convert sufficient TG
to FFA. In this way there could have been an insufficient
rise in endogenous CCK response to significantly reduce
intake at any TG dose. In support of this notion, it is
known that uptake of fat from capsules taken with water
and without simultaneous ingestion of food is delayed
(personal communication from Dr Rob Havenaar TNO
Research Zeist, The Netherlands). Also, in a previous
study with PinnoThin™ the effects on CCK response took
longer to develop for the TG compared to the FFA (60 min
rather than 30 min) [38]. A long term trial including 188
overweight men and women showed that pinolenic acid
was present in the blood at 4 and 8 months after daily
supplementation with 3 g of PinnoThin™ TG whereas
none was present in the control (olive oil) group (unpub-
lished results). This shows that PinnoThin™ TG is nor-
mally taken up and digested, i.e. FFA are released after
ingestion of PinnoThin™TG. When comparing FFA to TG
it also has to be taken into account that the total amount
of FFA will become available, whereas only two out of the
three fatty acids will become available for the TG. An effect
seen after 2 g of FFA should therefore be compared with
an effect of at least 3 g for the TG.
The mechanism of effect of PinnoThin™ is based on the
increase in satiety hormones seen in an earlier study [38].
The effect of PinnoThin™ on intestinal hormone release is
most likely mediated through chylomicron formation.
Fatty acids with a chain length of more than 12 carbon
atoms are absorbed into the circulation as chylomicrons.
A study in rats has shown that suppression of food intake
by long chain fatty acids is inhibited by blocking of chy-
lomicron transport through specific inhibitors [41]. CCK
signaling pathways are closely related to the transport of
chylomicrons [42]. The fact that only fatty acids with
more than 12 carbon atoms induce CCK speaks in favour
of this mechanism. This suggests that the fatty acids from
PinnoThin™ particularly affect chylomicron formation or
transport and thereby influence release of CCK. This
release leads to a delay in gastric emptying and in turn to
an increased feeling of satiety and a decreased appetite.
Overall, despite the lack of the TG form to affect intake or
appetite in this trial, these data are consistent with the
notion that fats have divergent effects on the expression of
appetite.
However, whilst CCK release from the proximal small
intestine may be critical in the acute effects of PinnoThin™
on within meal satiation or immediate post meal satiety,
such effects may not explain any observed reductions in
food intake across the whole day or any purported long-
term effects body weight. A variety of CCK anti-obesity
drugs in early clinical development have failed to progress
in later clinical trials presumably in part because of a lack
of efficacy beyond an initial reduction in hunger. Pin-
noThin™ induced GLP-1 released from the distal small
intestine may be of more importance in suppressing post-
meal intake by sustaining inter-meal satiety. The relative
contributions of these two hormones to the effects of Pin-
noThin™ on within-meal satiation, post-meal satiety and
associated changes in body weight over repeated dosing
remain to be clarified. In should also be noted it has been
shown that co-administration of CCK (in the form of
CCK-33) and GLP-1 does not produce an additive sup-
pression of food intake, although their effects on pre-meal
hunger were greater than when administered separately
[43].Page 5 of 10
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PinnoThin™ in both FFA and TG forms was well tolerated.
PinnoThin™ FFA employed in this study produced a
reduction in gram food intake consistent with previously
reported effects on appetite and CCK response. The lack of
significant effects of PinnoThin™TG on food intake and
appetite does not necessarily suggest that the TG form is
ineffective. Comparative data on PinnoThin™ FFA and TG
forms has become available since the study design which
suggests that the TG produces a delayed response on gut
hormone release. The time taken for TG to break down
into FFA form in the human gut is unknown, and this
could explain the delay. Similarly the effects of TG on gut
hormone release appear to differ in magnitude.
Materials and methods
Participants
Forty-two healthy women, aged 18–64, with a body mass
index (BMI) between 25–30 kg/m2 completed the study.
Volunteers were recruited by advertisement from the Uni-
versity of Liverpool and surrounding area of Merseyside in
the North West of England. Upon response to the adver-
tisements, individuals completed a standardized tele-
phone or email assessment to initially determine their
eligibility for the study. The specific inclusion criteria were
age between 18 and 65, overweight with a BMI of 25–30
kg/m2, non-smoker, interested in weight loss but not cur-
rently dieting, and able to attend the study centre at the
requisite times to eat the foods offered.
Screening
After the initial telephone/email assessment, potential
participants received detailed information on the proto-
col, completed a medical history and were invited to the
study centre, (The Kissileff Ingestive Behaviour Laboratory
in the School of Psychology, The University of Liverpool),
for a screening no more than 21 days before commencing
the study. All volunteers signed an informed consent form
before any study-specific procedures were undertaken.
The consent form stated that participants had read and
understood the information sheet. The protocol and con-
sent form were approved by the School of Psychology
Research Ethics Committee on May 15th 2006. The study
conformed to the British Psychological Society Code of
Practice and the UK Economic and Social Research Coun-
cil (ESRC) Research Ethics Framework (REF), and was also
in line with the relevant sections of the Declaration of
Helsinki. Volunteers received financial compensation for
their participation.
At the full screening, height, using a stadiometer to the
nearest cm, and weight, using standard calibrated scales to
the nearest 0.1 kg, were verified. Participants also com-
pleted a diet history, the restraint sub-scale of an eating
behaviour questionnaire [The Dutch Eating Behaviour
Questionnaire (DEBQ-R)] [44], and a depression scale
[Center for Epidemiologic Studies Depression Scale (CES-
D)] [45].
Exclusion criteria
Following screening, participants were excluded from the
study if they reported any of the following: significant
health issues likely to affect their well-being and/or appe-
tite; gastrointestinal symptoms requiring treatment; tak-
ing medication known to affect appetite; systemic or local
treatment likely to interfere with evaluation of the study
parameters; bariatric surgery; current adherence to a spe-
cific food avoidance diet; pregnancy; planning to become
pregnant or breastfeeding; general food allergies or spe-
cific allergies to milk, lactose, nuts, olives or any of the
study foods; dislike of more than 20% of the ad-libitum
study foods; extreme dietary restraint (>2 standard devia-
tions from the DEBQ-R mean) and significant levels of
depression (>16 on the CES-D). Women who were
employed in nutrition, dietetics, food research or the food
manufacturing industry were also excluded from the
study.
Study design
This was a double-blind, placebo-controlled study using a
randomized crossover design to evaluate the effects of
four weight-loss supplement doses against a placebo con-
trol. Study doses were administered acutely in a counter-
balanced sequence. Each treatment was separated by a
week. At the end of five visits every participant had
received each of the five treatments. The sample size was
calculated on the basis of the previous clinical trial of the
FFA form of PinnoThin™ [38]. Randomisation to the
study was by means of Latin squares [46]. Allocation of
participants to condition using the Latin Square was per-
formed by the experimenter. The company independently
randomly assigned the five doses to the five conditions
(A-E).
Materials and tools
Amount of food and water was recorded by weight scales
(Sartorius Model BP8100, Sartorius Ltd., Epsom, UK; 0.1
g accuracy) before and after meals to ascertain intake. Vis-
ual Analogue Scales (VAS) were used to rate degrees of
hunger, fullness, satisfaction, desire to eat, perception of
how much participants could eat (prospective consump-
tion), thirst and nausea. VAS consist of 100 mm horizon-
tal lines anchored by "not at all" and "extremely" at
opposite ends, upon which participants record with a ver-
tical line their subjective ratings. For example, hunger was
rated along a 100 mm line that was preceded by the ques-
tion "how hungry do you feel at this moment?" and
anchored on the left by "not at all hungry" and on the
right by "extremely hungry". These questionnaires were
completed immediately before and after each meal,Page 6 of 10
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the test day [47-49].
PinnoThin™ and placebo were supplied in the form of six
capsules per dose per test day. Each capsule contained 1 g
of oil and in total the subjects received 2 g, 4 g or 6 g Pin-
noThin™ Triglyceride (TG), or 2 g of PinnoThin™ free fatty
acid (FFA), with 2, 4 or 6 g of olive oil (placebo) (Table 3).
Olive oil was chosen as a placebo, based on the fatty acid
content of PinnoThin™ and its wide use in the diet. Olive
oil consists mainly of oleic acid, which is also found in
PinnoThin™ (25%). Furthermore, the other main fatty
acids in PinnoThin™ are linoleic (46%) and pinolenic
acid (15%), both having the same chain length as oleic
acid (C18). Olive oil was therefore thought to be an
appropriate control. The fatty acid components of the
product and placebo are shown in Table 4. The capsules
were packaged in coded containers labelled A to E to
ensure the double-blind status of the study.
Study procedure
On each day preceding the study day participants were
asked to keep their food intake, fluid intake and activity
levels similar and to record these in a diary from 5 pm
until they retired for the night. They were asked not to
consume any alcohol and not to eat or drink anything
except water from 12 midnight until they attended the
study centre the following morning.
At 8.30 am on each test day participants attended the
study centre where they consumed a fixed-load breakfast
(496 kcal; Table 5). Participants were then free to leave the
study centre. They were instructed not to eat or drink any-
thing except water that was provided by the study. Thirty
minutes before lunch (three and a half hours after break-
fast) the 6 capsules were provided with 200 ml water.
They were instructed to swallow all the capsules with as
much of the water as required. Following a rest period an
ad-libitum lunch was served (Table 6). Participants were
instructed to eat as much as they liked from the choice of
foods and water offered, taking as long as they wished,
and signalling when they had finished. Participants were
then free to leave the study centre, with instructions not to
eat or drink anything except the provided water. Partici-
pants returned for supper four hours later and were served
a hot ad-libitum evening meal (Table 6). Again, they were
asked to consume as much as they wanted, taking as long
as they wished and signalling when they had finished. The
study day was then complete and participants were not
given any food restrictions for the remainder of the test
day. As stated, VAS were completed throughout the day.
The same procedure was followed on all test days.
Test meals
A standard fixed-load breakfast (496 kcal) was dispensed
to participants in all conditions (Table 5). In addition to
the fixed-load breakfast, at the first visit, participants were
offered a hot drink of tea or coffee with additional milk
(35 g) and sugar if desired. If requested, this drink had to
be consumed on each subsequent visit. The ad-libitum
lunch consisting of a selection of 20 cold items, is shown
Table 5: Amount and energy composition of fixed load breakfast
Food Amount (g)
Kellogg's Cornflakes 30
Semi-skimmed UHT Milk 125
Orange Juice 200
Sliced White Bread (toasted) 60
Flora Margarine 10
Strawberry Jam (+ hot drink, 35 g milk and sugar if 
required)
20
TOTAL WEIGHT 445
TOTAL KCALS 496
10% Energy from Protein, 17% Energy from Fat, 73% Energy from 
Carbohydrate
Table 3: Content of study six capsules given 30 minutes before lunch in the five experimental conditions
Capsule 1 Capsule 2 Capsule 3 Capsule 4 Capsule 5 Capsule 6
Placebo 1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
2 g FFA 1 g FFA 1 g FFA 1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
2 g TG 1 g TG 1 g TG 1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
4 g TG 1 g TG 1 g TG 1 g TG 1 g TG 1 g Placebo 
(olive oil)
1 g Placebo 
(olive oil)
6 g TG 1 g TG 1 g TG 1 g TG 1 g TG 1 g TG 1 g TG
Table 4: Olive and Korean Pine Nut oils
Product Fatty Acid Components
PinnoThin 15% pinoleic 25% oleic 45% linoleic
Olive oil 12% palmitic 71% oleic 10% linoleicPage 7 of 10
(page number not for citation purposes)
Lipids in Health and Disease 2008, 7:6 http://www.lipidworld.com/content/7/1/6in Table 6. Supper was an ad-libitum hot pasta meal with
a selection of desserts (Table 6). The ad-libitum meals
(lunch and supper) were designed to offer a selection of
high and low fat savoury and sweet food items. The nutri-
tional content of all food items is also shown in Table 6.
Lunchtime was fixed at precisely 4 hours after breakfast
and supper 4 hours after lunch. All meals were served in
individual booths in the test study centre.
Statistical analysis
The primary outcome, intake at the test meals, was ana-
lysed for amount consumed (in grams and kcal) using
within-subject analysis of variance (ANOVA) with condi-
tion (0 g, 2 g, 4 g, 6 g PinnoThin TG, and 2 g PinnoThin
FFA) as a within-subject factor. Because breakfast was
fixed, this was not included in the statistical analysis.
Intake at lunch was analysed in relation to macronutrient
content using a 2-way within-subjects ANOVA with con-
dition (0 g, 2 g, 4 g, 6 g PinnoThin TG, and 2 g PinnoThin
FFA) and macronutrient (fat, carbohydrate and protein)
as within subject factors. The 20 food items offered at the
ad-libitum lunch were further analysed according to vari-
ation in fat content and taste. Foods were grouped into
high fat savoury (HFSA), low fat savoury (LFSA), high fat
sweet (HFSW), low fat sweet (LFSW) and fruit and vegeta-
bles (FTVG) sets. These food groups were analysed using a
2-way within-subjects ANOVA with condition (0 g, 2 g, 4
g, 6 g PinnoThin TG, and 2 g PinnoThin FFA) and taste
(HFSA, LFSA, HFSW and LFSW) as within-subjects factors.
The secondary outcome measures of the study were
changes in ratings of appetite such as hunger, fullness,
prospective consumption, and desire to eat, assessing the
nature of any product-induced reductions in food intake.
These parameters rated on the VAS were analysed using
within-subject ANOVA for repeated measures with condi-
tion (0 g, 2 g, 4 g, 6 g PinnoThin TG, 2 g PinnoThin FFA)
and time (pre-breakfast, post-breakfast, 10 am, 11 am, 12
pm, pre-dose, pre-lunch, post-lunch, 2 pm, 3 pm, 4 pm,
pre-supper and post-supper) as within-subject factors. If a
time-by-condition interaction effect was found signifi-
cant, paired t-tests would have been conducted at each rat-
ing time between conditions. Z-score analysis (individual
scores measured against the mean of all other scores) was
used to identify outliers. Scores of <-2 or >+2 were consid-
ered outliers and analysis was re-run following removal of
Table 6: Nutritional content of foods offered at test meals
Food No of Items Amount 
(g in serving)
Protein 
(g in serving)
Fat 
(g in serving)
CHO 
(g in serving)
Kcal in serving
LUNCH
Tesco Medium Sliced White Bread 4 slices 144 11.66 2.30 65.52 329.76
Kallo Low Fat Rice Cakes 4 pieces 30 2.40 0.84 23.61 111.60
Asda Turkey Slices 5 slices 62.5 11.69 3.13 1.50 80.63
Tesco Danish Salami 5 slices 44.6 5.89 20.52 3.12 220.78
Tesco Value Cottage Cheese serving 150 21.45 2.25 5.10 127.50
Asda Cheese Substitute serving 100 25.00 21.10 2.50 300.00
Flora Light Margarine 4 packs 40 Trace 2.36 Trace 21.20
Butter 4 packs 27.2 0.14 22.22 Trace 200.46
Tomato Approx. 2 135 Trace Trace Trace Trace
Cucumber serving 80 Trace Trace Trace Trace
Lettuce Approx. 1/4 100 Trace Trace Trace Trace
Walker's Ready Salted Crisps 1 packet 25 1.63 8.50 12.25 132.50
Tesco Value Jaffa Cakes 4 cakes 45.2 2.17 3.98 30.56 167.24
Tesco Jelly Babies 20 sweets 120 6.36 0.00 96.84 412.80
Tesco Chocolate Mousse 1 pot 67 2.41 5.63 18.49 134.00
Asda Apple Slices 1 pack 80 0.24 0.08 9.60 40.00
Tesco Value Chocolate Chip Cookies serving 100 4.80 26.10 64.70 513.00
Asda Smart Price Cheese and Tomato 
Pizza
1 66.5 4.66 5.32 26.60 172.90
Mayonnaise 5 packets 60 0.96 48.60 0.96 415.39
Mustard serving 36 2.52 3.20 6.01 63.00
SUPPER
Tesco Fusilli serving 250 33.00 5.00 171.25 862.50
Tesco Value Garlic Bread 3 slices 50 4.05 6.55 21.00 159.00
Tesco Value Fruit Cocktail 1 tin 390 1.56 0.39 42.90 183.30
Ragu Pasta Sauce 1 jar 460 5.40 0.45 31.50 148.50
Asda Cheese Substitute serving 50 12.50 10.55 1.25 150.00
Tesco Dark Choc Ice 1 bar 80 2.48 16.96 21.92 248.00Page 8 of 10
(page number not for citation purposes)
Lipids in Health and Disease 2008, 7:6 http://www.lipidworld.com/content/7/1/6outliers. Analysis was performed using SPSS for Windows,
Version 13 (SPSS Inc., Chicago, US). The assumptions of
the ANOVA model were tested and if homogeneity of var-
iance was not found, multivariate tests were adopted for
that variable. All tests are two-tailed unless stated. The
data remained blinded until after the primary and second-
ary outcomes were analysed.
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